KRAS as a Therapeutic Target
1Frederick National Laboratory for Cancer Research, Frederick, Maryland. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California. mccormick@cc.ucsf.edu.
Abstract:
KRAS proteins play a major role in human cancer, but have not yielded to therapeutic attack. New technologies in drug discovery and insights into signaling pathways that KRAS controls have promoted renewed efforts to develop therapies through direct targeting of KRAS itself, new ways of blocking KRAS processing, or by identifying targets that KRAS cancers depend on for survival. Although drugs that block the well-established downstream pathways, RAF-MAPK and PI3K, are being tested in the clinic, new efforts are under way to exploit previously unrecognized vulnerabilities, such as altered metabolic networks, or novel pathways identified through synthetic lethal screens. Furthermore, new ways of suppressing KRAS gene expression and of harnessing the immune system offer further hope that new ways of treating KRAS are finally coming into view. These issues are discussed in this edition of CCR Focus.
Insights
Targeting KRAS proteins in cancer is challenging but new strategies are emerging. Researchers are exploring direct KRAS targeting, pathway inhibition, and novel vulnerabilities for effective cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- KRAS proteins are crucial in human cancers but historically resistant to therapies.
- Existing therapeutic approaches focus on downstream pathways like RAF-MAPK and PI3K.
Discussion:
- New strategies involve direct KRAS targeting, inhibiting KRAS processing, and identifying KRAS-dependent survival targets.
- Exploiting previously unrecognized vulnerabilities such as metabolic alterations and synthetic lethal interactions is a key focus.
- Novel approaches include suppressing KRAS gene expression and leveraging the immune system.
Key Insights:
- Despite challenges, renewed efforts in drug discovery and pathway analysis are advancing KRAS-targeted therapies.
- Exploiting KRAS vulnerabilities offers new hope for treating cancers driven by this oncogene.
- A multi-pronged approach combining direct targeting, pathway modulation, and novel strategies is crucial.
Outlook:
- Further research into KRAS signaling and cancer dependencies will uncover new therapeutic avenues.
- Advancements in understanding KRAS biology promise more effective and targeted cancer treatments.
- The development of novel therapies offers hope for improved patient outcomes in KRAS-driven cancers.
More Related Videos
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:00Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase